0.6 ML methylnaltrexone bromide 20 MG/ML Injection [Relistor] — RxCUI 979115
RxNorm drug concept · Semantic branded drug
RxCUI 979115
Semantic branded drug · SBD
● Current RxNorm concept 3 FDA products
6 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI979115
Official name0.6 ML methylnaltrexone bromide 20 MG/ML Injection [Relistor]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as0.6 ML Relistor 20 MG/ML Injection; RELISTOR 12 MG in 0.6 ML Injection; Relistor 12 MG per 0.6 ML Injection
FDA products mapped3
Package NDCs mapped6
Reported Medicaid activity (SDUD)18,616 prescriptions · 35 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Methylnaltrexone Injection: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- No — that's actually the key feature of this medicine. Relistor is designed to work only in your gut, not in your brain. It blocks opioid receptors in the digestive tract to reliev...
- Will Relistor injection reduce the effectiveness of my pain medication?
- Relistor is absorbed into your system quite quickly after a subcutaneous injection — it reaches peak levels in your blood within about 15 to 30 minutes. Many people find they need...
- How soon after the injection should I expect results?
🕸️ Concept Web — How 0.6 ML methylnaltrexone bromide 20 MG/ML Injecti... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
0.6 ML methylnaltrexone bromide 20 MG/ML Injection [Relistor]
RxCUI 979115 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
Methylnaltrexone
29899IN -
Methylnaltrexone bromide
979111PIN
-
Methylnaltrexone
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Relistor
796436BN
-
Relistor
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Methylnaltrexone Injection
1659739SCDF -
Methylnaltrexone bromide Injection
2645365SCDFP -
Methylnaltrexone Injectable Product
1156739SCDG -
Methylnaltrexone bromide Injectable Product
2659614SCDGP -
Methylnaltrexone Injection [Relistor]
1659741SBDF -
Methylnaltrexone bromide Injection [Relistor]
2657956SBDFP -
Relistor Injectable Product
1180709SBDG -
Injection
1649574DF - +1 more in this family
-
Methylnaltrexone Injection
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
0.6 ML methylnaltrexone bromide 20 MG/ML Injection
979113SCD -
Methylnaltrexone bromide 20 MG/ML
979112SCDC -
Methylnaltrexone bromide 20 MG/ML [Relistor]
979114SBDC
-
0.6 ML methylnaltrexone bromide 20 MG/ML Injection
Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
0.6 ML methylnaltrexone bromide 20 MG/ML Injection
SCD · 979113 -
Methylnaltrexone bromide 20 MG/ML
SCDC · 979112 -
Methylnaltrexone Injection
SCDF · 1659739 -
Methylnaltrexone bromide Injection
SCDFP · 2645365 -
Methylnaltrexone Injectable Product
SCDG · 1156739 -
Methylnaltrexone bromide Injectable Product
SCDGP · 2659614
Brand-Name Concepts
-
Methylnaltrexone bromide 20 MG/ML [Relistor]
SBDC · 979114 -
Methylnaltrexone Injection [Relistor]
SBDF · 1659741 -
Methylnaltrexone bromide Injection [Relistor]
SBDFP · 2657956 -
Relistor Injectable Product
SBDG · 1180709 -
Relistor
BN · 796436
📦 FDA Products & Package NDCs
3 products · 6 package NDCs
6 package NDCs map to RxCUI 979115 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 65649-0150-06 | 1 BOTTLE in 1 CARTON (65649-150-06) / 6 TABLET in 1 BOTTLE | Relistor | Salix Pharmaceuticals, Inc. | 2016-07-19 |
| 65649-0150-90 | 90 TABLET in 1 BOTTLE (65649-150-90) | Relistor | Salix Pharmaceuticals, Inc. | 2016-07-19 |
| 65649-0551-02 | 1 VIAL, SINGLE-DOSE in 1 CARTON (65649-551-02) / .6 mL in 1... | Relistor | Salix Pharmaceuticals, Inc. | 2008-04-24 |
| 65649-0551-03 | 7 BLISTER PACK in 1 CARTON (65649-551-03) / 1 SYRINGE in 1... | Relistor | Salix Pharmaceuticals, Inc. | 2008-04-24 |
| 65649-0551-07 | 1 BLISTER PACK in 1 CARTON (65649-551-07) / 1 SYRINGE in 1... | Relistor | Salix Pharmaceuticals, Inc. | 2008-04-24 |
| 65649-0552-04 | 7 BLISTER PACK in 1 CARTON (65649-552-04) / 1 SYRINGE in 1... | Relistor | Salix Pharmaceuticals, Inc. | 2008-04-24 |
Observed labelers:
Salix Pharmaceuticals, Inc. (6)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.